Imagine a master key that can unlock and stop several different types of dangerous viruses at once. Instead of taking dozens of pills over several weeks, this technology aims to provide a simple, one-dose treatment. It targets a family of viruses that cause diseases like Dengue and Zika, which currently have no effective cures.
There are currently no effective treatments or vaccines for flaviviral infections like Dengue and Zika. This creates a global health emergency with billions of euros in economic losses and millions of infections annually.
A first-in-class broad-spectrum antiviral drug substance and product. The development includes a unique one-dosing regime and the completion of CMC studies for clinical trial entry.
If you are a pharmaceutical giant dealing with the lack of effective flavivirus treatments — this project developed a first-in-class drug candidate that targets Dengue, West-Nile, and Zika. It offers a unique selling point through a one-dosing regime, potentially replacing complex 30-pill regimens.
If you are a health agency dealing with pandemic-prone outbreaks affecting 40% of the global population — this project developed a broad-spectrum antiviral. This tool helps manage outbreaks and reduce the €9B in direct and indirect costs associated with these infections.
If you are a CRO dealing with the need for high-efficiency clinical trial designs — this project developed a drug substance ready for Phase 1 and 2a trials. The simplified dosing regime reduces patient burden and improves trial adherence.
Based on available project data, the specific price per dose is not mentioned, but the project aims to reduce the €9B in direct and indirect costs caused by flaviviral infections.
The project has performed extensive studies on CMC (Chemistry, Manufacturing, and Controls), drug substance, and drug product to ensure they fulfill criteria for clinical studies.
The project results regarding the one-dosing regime are expected to lead to additional IPR protecting Protinhi's technology.
Protinhi has prepared the necessary information for scientific advice from regulatory bodies such as the EMA.
The project period runs from 2023-03-01 to 2026-08-31, focusing on Phase 1 and Phase 2a clinical trials to obtain proof-of-concept in humans.
The project is led by a single partner, PROTINHI BV, a Dutch SME. This 100% industry-led consortium indicates a highly focused commercial drive, as the company is directly managing the transition from pharmaceutical development to human clinical trials without academic partners.
Contact PROTINHI BV in the Netherlands for partnership opportunities regarding Phase 2a trials.
Contact us to explore licensing opportunities for this first-in-class flavivirus antiviral.
